Targeting KRAS in Non-Small Cell Lung Cancer

Targeting KRAS in Non-Small Cell Lung Cancer

Kirsten Rat Sarcoma viral oncogene homolog (KRAS) is the most frequently altered oncogene in Non-Small Cell Lung Cancer (NSCLC). KRAS mutant tumors constitute a heterogeneous group of diseases, different from other oncogene-derived tumors in terms of biology and response to treatment, which hinders...

Full description

Bibliographic Details
Main Authors: Elena Corral de la Fuente, Maria Eugenia Olmedo Garcia, Ana Gomez Rueda, Yolanda Lage, Pilar Garrido
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-01-01
Series:Frontiers in Oncology
Subjects:
targeted therapy
NSCLC
KRAS
immunotherapy
drug resistance
lung cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.792635/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.792635/full

Similar Items